Form 4: Sutro Biopharma Director Acquires Stock Options

Sutro Biopharma director Jagpal Sukhi was granted 10,000 stock options with an exercise price of $26.09, vesting over time.

Summary

• Jagpal Sukhi, a Director at Sutro Biopharma, Inc., was granted 10,000 stock options on June 5, 2026.
• The options have an exercise price of $26.09 per share.
• Vesting of the options will occur monthly, with 8.33% of the total award vesting each month.
• The first tranche is set to vest on July 5, 2026.
• The award will be fully vested and exercisable by June 5, 2027, or the date of the issuer's 2027 annual stockholders meeting, whichever comes first.
• These options represent the right to buy 10,000 shares of Sutro Biopharma's Common Stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard compensation event for a director rather than a significant financial event for the company.

Positives

• Director compensation through stock options aligns management interests with shareholder value.
• The grant of options suggests confidence in the company's future stock performance.
• The vesting schedule encourages long-term commitment from the director.

Negatives

• The exercise price of $26.09 indicates that the options will only be profitable if the stock price increases significantly above this level.
• The filing does not provide details on the total compensation package or the rationale behind this specific grant.

Risks

• The value of the stock options is directly tied to the future performance of Sutro Biopharma's stock, which is subject to market volatility and company-specific risks.
• If the company's stock price does not exceed the exercise price of $26.09, the options may expire worthless.

Future Outlook

The vesting schedule and expiration date of the stock options suggest an expectation of continued company operations and potential stock price appreciation over the next several years.

Industry Context

StockSavvy.ai notes that the granting of stock options to directors is a common practice in the biopharmaceutical industry, used to incentivize leadership and align their financial interests with the long-term success of the company, especially given the inherent volatility and long development cycles typical in this sector.

Stakeholder Impact

• Shareholders: The alignment of director incentives with stock performance can be viewed positively, potentially leading to decisions that benefit shareholders.
• Employees: The granting of options to directors may reflect a broader compensation philosophy that includes equity-based incentives, though this filing specifically pertains to a director.

Next Steps

• The director will receive monthly vesting of stock options.
• The options will become fully exercisable by June 5, 2027, or the 2027 annual stockholders meeting.

Key Dates

Keywords

Sutro Biopharma, STRO, Form 4, Stock Options, Director Compensation, Beneficial Ownership, SEC Filing, Insider Trading